GlassScriptPhysician profile
Laura M Mason
NPI 1831392828
$8,728.76
in general payments reported to CMS, 2019-2025
55 companies · $2,100 in 2025
The $2,100 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,195 · 2020: $540 · 2021: $376 · 2022: $735 · 2023: $1,475 · 2024: $2,307 · 2025: $2,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,801 · Education: $81.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,800.74 |
| Education | $81.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,350.49 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $1,161.21 | 2021-2025 | |
| Mdd US Operations, LLC | $673.01 | 2019-2025 | Gocovri, Xadago, Apokyn |
| Novartis Pharmaceuticals Corporation | $593.79 | 2019-2025 | |
| Biogen, INC. | $486.37 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Supernus Pharmaceuticals, INC. | $420.46 | 2019-2022 | |
| Tg Therapeutics, INC. | $409.09 | 2023-2025 | |
| Argenx US, INC. | $339.87 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $283.53 | 2019-2024 | Aimovig |
| Alexion Pharmaceuticals, INC. | $258.87 | 2019-2025 | Ultomiris |
| Lilly USA, LLC | $236.51 | 2021-2025 | Reyvow, Emgality, Amyvid |
| Amneal Pharmaceuticals LLC | $219.21 | 2019-2024 | Rytary |
| Pfizer INC. | $205.55 | 2019-2025 | |
| Celgene Corporation | $167.28 | 2021-2025 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $124.80 | 2020-2021 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Mason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.